ストックスクリーナーアプリを入手
119.77
0.72%
0.815
アフターアワーズ：
119.86
0.095
+0.08%
前日終値:
$118.95
開ける：
$118.95
24時間の取引高:
1.62M
Relative Volume:
0.77
時価総額：
$15.89B
収益：
$1.08B
当期純損益:
$-433.19M
株価収益率:
-35.22
EPS:
-3.4004
ネットキャッシュフロー:
$-225.09M
1週間 パフォーマンス:
+22.01%
1か月 パフォーマンス:
+34.75%
6か月 パフォーマンス:
+11.15%
1年 パフォーマンス:
+215.28%
1日の値動き範囲:
$115.30
$120.35
1週間の範囲:
$100.48
$121.01
52週間の値動き範囲:
$37.73
$121.01
Guardant Health Inc Stock (GH) Company Profile
Compare GH vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
119.80 | 15.77B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-09-25 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 再開されました | Wells Fargo | Overweight |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-28 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-26 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-11-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 開始されました | Craig Hallum | Buy |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-04-28 | 再開されました | BTIG Research | Buy |
| 2022-02-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2022-02-24 | 繰り返されました | Citigroup | Buy |
| 2022-02-24 | 繰り返されました | Cowen | Outperform |
| 2022-02-24 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-24 | 繰り返されました | SVB Leerink | Outperform |
| 2022-02-24 | 繰り返されました | Stifel | Buy |
| 2022-02-24 | 繰り返されました | Wells Fargo | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-11 | 開始されました | Stifel | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-06-12 | 開始されました | BTIG Research | Buy |
| 2020-02-21 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-08-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-04-16 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | JP Morgan | Overweight |
| 2018-10-29 | 開始されました | William Blair | Outperform |
すべてを表示
Guardant Health Inc (GH) 最新ニュース
BTIG raises Guardant Health stock price target on FDA approval By Investing.com - Investing.com Canada
Guardant Health, Inc. (GH) Stock Analysis: 48.3% Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Guardant gets FDA nod for next-gen cancer mutation blood test - Mugglehead Investment Magazine
Guardant wins FDA nod for Guardant360 Liquid CDx cancer test - MSN
A Look At Guardant Health’s Valuation After Its Recent Share Price Surge - Yahoo Finance
Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed? - Yahoo Finance
Guardant Health Stock 5-Day Winning Spree: Stock Climbs 25% - Trefis
Guardant Health Stock On Fire: Up 25% With 5-Day Winning Streak - Trefis
Insider Sell: John Saia Sells 20,000 Shares of Guardant Health I - GuruFocus
Guardant Health director Ian T. Clark disposes of $735k in shares - Investing.com UK
Guardant Health chief legal officer sells $2.13m in stock - Investing.com UK
Guardant Health director Ian T. Clark disposes of $735k in shares By Investing.com - Investing.com South Africa
Guardant Health chief legal officer sells $2.13m in stock By Investing.com - Investing.com Australia
Guardant Health insider cashless exercise reported (NASDAQ: GH) - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insider Sold Shares Worth $23,076,690, According to a Recent SEC Filing - Moomoo
Guardant Health Insider Sold Shares Worth $2,130,229, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) Chief Legal Officer sells 20,000 shares in open-market trades - Stock Titan
Guardant Health (GH) co-CEO’s family trust sells 210K shares of stock - Stock Titan
Family trust of Guardant Health (NASDAQ: GH) director sells 6,876 shares in open market - Stock Titan
Guardant Health (NASDAQ: GH) director sells 1,250 shares after exercising options - Stock Titan
Guardant Health stock gains on early FDA approval for G360 test By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 120.74 USD By Investing.com - Investing.com Nigeria
Research Alert: CFRA Maintains Buy Rating On Shares Of Guardant Health - Moomoo
Guardant Health stock hits 52-week high at 120.74 USD - Investing.com
Guardant Health stock gains on early FDA approval for G360 test - Investing.com Australia
Guardant wins FDA approval for updated liquid biopsy - MedTech Dive
NORTH SQUARE DYNAMIC SMALL CAP FUND's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health leaps on a major win in cancer detection; will shares break out? - MSN
Guardant Health (GH) Shares Rise Following FDA Approval of Guard - GuruFocus
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum - simplywall.st
Guardant Health (GH) Gains FDA Approval for New Liquid Biopsy Te - GuruFocus
Guardant Health secures FDA approval for expanded liquid biopsy test - MSN
Guardant Health (GH) Form 144 lists brokered proposed sales and restricted stock lapses - Stock Titan
Guardant Health (NASDAQ: GH) affiliate sale notice; 1,300 shares sold previously - Stock Titan
Guardant Health Stock Climbs As Q1 Beat Fuels Bullish Targets - StocksToTrade
Guardant Health receives FDA approval for expanded liquid biopsy test By Investing.com - Investing.com Australia
Guardant Health Stock Climbs As Growth Story Accelerates - timothysykes.com
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat - StocksToTrade
Why is Guardant Health stock surging today? By Investing.com - Investing.com Australia
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestGuardant Health (NASDAQ:GH) - Benzinga
FDA approval advances personalized cancer diagnostics - BioWorld News
Guardant Health Stock Jumps 10% to $108 on Momentum From Record Q1 Revenue Beat and Raised Guidance - International Business Times Australia
Guardant Health Stock Builds Momentum After Q1 Beat And Analyst Upgrades - timothysykes.com
Guardant Health Receives FDA Approval for New Cancer Test - Intellectia AI
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Guardant wins FDA nod for Guardant360 Liquid CDx (GH:NASDAQ) - Seeking Alpha
Guardant Health Receives FDA Approval for New Liquid Biopsy - Intellectia AI
Guardant Health receives FDA approval for expanded liquid biopsy test - Investing.com
Guardant Health Says US FDA Approved Liquid Biopsy Test - Moomoo
Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint - marketscreener.com
Guardant Health Inc (GH) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.39%
大文字化:
|
ボリューム (24 時間):